New drug AT-02 tested for long-term safety in rare disease
NCT ID NCT05951049
First seen May 13, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study looks at the long-term safety of an experimental drug called AT-02 for people with systemic amyloidosis, a rare disease where abnormal proteins build up in organs. About 120 adults who have already been in an earlier study will receive AT-02 and be monitored for side effects and how the drug works in the body. The goal is to see if AT-02 is safe and tolerable over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS; SYSTEMIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Kansas City
Kansas City, Kansas, 64111, United States
-
OHSU (Oregon Health & Science University)
Portland, Oregon, 97239, United States
-
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.